Contact this trialFirst, we need to learn more about you.
Growth Hormone Receptor Antagonist
Pegvisomant for Growth Hormone Excess
Recruiting2 awardsPhase 3
Bethesda, Maryland
This trial is testing the role of the drug pegvisomant in children and adolescents with gigantism. Eligible participants must be aged 2-18, have GH excess, and be unresponsive or ineligible for current treatments. The study will last 60 weeks and include several visits with medical history and physical exams, questionnaires, heart and liver tests, and blood and urine tests. Participants will also have an MRI and hand X-ray at the baseline and 12-month visits.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service